Oncodona

Oncodona
Benefits
Indications

What is the Oncodona Test?

It is the most advanced genetic test for early identification of predisposition to inherited cancer.

Oncodona uses Next Generation Sequencing (NGS) to analyze genetic information present in a panel of 21 genes, including BRCA1 and BRCA2 genes, in order to locate harmful mutations.

The presence of a change or mutation in one of these genes assumes that the female carrier has an increased risk of developing breast and ovarian tumours, or other related cancers.

What is the procedure?

Why use Oncodona test?

The performance of the test, if positive, can be used to adopt follow-up and personalized early detection measures of the patient and their relatives.
Carriers already diagnosed will be more likely to have another type of cancer.
A positive test result may also have important health implications for family members, and even future generations.

What genes are included in the Oncodona test?

In addition to the BRCA1 and BRCA2 genes, the Oncodona test analyzes 19 more genes associated with risk of breast and ovarian cancer, which makes it a more complete test:

Who should use Oncodona test?

Women diagnosed with breast cancer and BRCA1 and BRCA2 negative genetic test. In these typesof patients Oncodona can find a mutation in up to 4% of women.
Women with a family member diagnosed with breast and ovarian cancer.
Women of general population without known increased risk.

Test limitations

It is reported that, in a particular case, the Oncodona test may not identify a mutation in the genes studied, even though a mutation may actually exist in one of the genes.
It is also reported that the Oncodona test can identify changes for which there is currently no medical consensus as to whether such changes pose an increased risk of developing cancer.
The Oncodona test does not include all genes for which the medical literature indicates a possible association with breast and/or ovarian cancer.

Documentation

Specialists documents

Brochure

Download

Scientific evidence

Relevant related studies:

Malone et al. Cancer Res 2006;66(16):8297-8308

JAMA Oncol. 2015;1(7):943-951. doi:10.1001/jamaoncol. 2015.2690

Kufe DW, Pollock RE, Weichselbaum RR, et al., editors. Holland-Frei Cancer Medicine. 6th edition. Hamilton (ON): BC Decker; 2003.

아이지노믹스 소개

아이지노믹스는 생식 유전자 검사 서비스에 특화된 의료 임상 테스트 연구소에서 불임이 더 이상 불가능한 장벽이 아닌 세계의 실현을 위해 노력하고 있습니다. 전세계 의료기관과 임신 전문의들과 함께 우리는 임신을 원하는 부부의 인생을 바꿀 생명 잉태의 성공을 연구하고 있습니다.

Other services

CGT

(보인자 선별 검사)
유전 질환은 치유 할 수는 없지만, 예방할 수 있습니다.

더 알아보기

PGD/PGT-M

(단일 유전자 질환에 대한 착상 전 진단)
예비부모에게 유전 질환이 있는 경우에 유전 질환 발현 위험성을 예측하여 건강한 아기를 낳도록 도와드립니다.

더 알아보기

PGS/PGT-A

(착상 전 배아 염색체 이수성 검사)
염색체 수적 이상이 없는 배아를 선별하여 임신율 향상에 기여합니다.
(산부인과 학회의 지침을 준수합니다.)

더 알아보기

Mutations in BRCA1 or BRCA2 genes are 20-fold higher in women with precocious breast cancer

Mutations in BRCA1 and BRCA2 account for ≈ 5% of breast cancers and 10-15% of ovarian cancers.

Oncodona test offers genetic counselling by experts

Oncodona analyzes a panel of 21 genes

What is the Oncodona Test?

What is the procedure?

Why use Oncodona test?

What genes are included in the Oncodona test?

Who should use Oncodona test?

Test limitations

Brochure

Relevant related studies:

Can we help you?

아이지노믹스 소개

Learn about genetics

NEW COURSES AVAILABLE:

Non Invasive PGS, Maria Vera

CGT

PGD/PGT-M

PGS/PGT-A

Early risk detection of hereditary breast and ovarian cancer.

Mutations in BRCA1 or BRCA2 genes are 20-fold higher in women with precocious breast cancer

Mutations in BRCA1 and BRCA2 account for ≈ 5% of breast cancers and 10-15% of ovarian cancers.

Oncodona test offers genetic counselling by experts

Oncodona analyzes a panel of 21 genes

What is the Oncodona Test?

What is the procedure?

Why use Oncodona test?

What genes are included in the Oncodona test?

Who should use Oncodona test?

Test limitations

Brochure

Relevant related studies:

Can we help you?

아이지노믹스 소개

Learn about genetics

NEW COURSES AVAILABLE:

Non Invasive PGS, Maria Vera

Other services

CGT

PGD/PGT-M

PGS/PGT-A

아이지노믹스 글로벌 미디어 게재 정보